Loading clinical trials...
Loading clinical trials...
A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera) on Glycemic Control in Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled on a Minimum of Two Oral Anti Diabetic Agents
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
Age
35 - 80 years
Sex
ALL
Healthy Volunteers
No
Pfizer Investigational Site
La Jolla, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Columbus, Georgia, United States
Pfizer Investigational Site
Overland Park, Kansas, United States
Pfizer Investigational Site
New Orleans, Louisiana, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Start Date
April 1, 2005
Completion Date
May 1, 2007
Last Updated
April 17, 2008
1,100
Estimated participants
Inhaled Insulin
DRUG
Lead Sponsor
Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07480161